<SEC-DOCUMENT>0001144204-19-023649.txt : 20190503
<SEC-HEADER>0001144204-19-023649.hdr.sgml : 20190503
<ACCEPTANCE-DATETIME>20190503162359
ACCESSION NUMBER:		0001144204-19-023649
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190502
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190503
DATE AS OF CHANGE:		20190503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		19796527

	BUSINESS ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv520581_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C.&nbsp;20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): May 2, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><B>000-26770</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><B>22-2816046</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or Other Jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Incorporation)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>20 Firstfield Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Gaithersburg, Maryland 20878</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former name or former
address, if changed since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Trading Symbol(s)</B></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock, Par Value $0.01 per share</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">NVAX</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">The Nasdaq Global Select Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT><BR></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.75in; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: -3in"><FONT STYLE="font-size: 10pt; color: #211D1E">Emerging
growth company&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #211D1E">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02. Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>First Quarter Financial Results</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 2, 2019,
Novavax, Inc. (the &ldquo;Company&rdquo;) issued a press release announcing the Company&rsquo;s financial results for the quarter
ended March 31, 2019. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information
in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><B>Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tv520581_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv520581_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt; background-color: white">Press release, dated May 2, 2019, regarding the Company&rsquo;s financial results for the quarter ended March</FONT> <FONT STYLE="font-size: 10pt">31, 2019<FONT STYLE="background-color: white">.</FONT></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0.25in"> Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>NOVAVAX,&nbsp;INC.</B></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ John A. Herrmann III</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0">John A. Herrmann III</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Title:&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Senior Vice President, General<BR>
 Counsel and Corporate Secretary</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Date: May 3, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv520581_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 30.75pt; width: 198pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Novavax
Reports First Quarter 2019 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Company to Host Conference
Call Today at 4:30 p.m. ET</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Gaithersburg,
MD, May 2, 2019</B> &ndash; Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for
the first quarter ended March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>First
Quarter 2019 and Subsequent Operational Highlights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>ResVax&trade; Program</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In February 2019,
Novavax announced top-line data from the Prepare&trade; trial, which was designed to determine the efficacy of ResVax&trade; against
medically significant respiratory syncytial virus (RSV)-positive lower respiratory tract infection (LRTI) in infants. ResVax is
the first RSV vaccine to demonstrate efficacy in infants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In April 2019,
Novavax presented additional results at the World Vaccine Congress in Washington, D.C. from the Prepare trial of ResVax. Although
the Prepare trial results did not meet the pre-specified primary efficacy endpoint, it demonstrated efficacy against RSV LRTI hospitalizations,
a pre-specified secondary endpoint. RSV LRTI hospitalization is not only an important indication of the severity of RSV disease
in infants, it also reflects a significant economic burden to global health systems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>NanoFlu&trade; Program</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In January 2019,
Novavax announced positive top-line results of its Phase 2 clinical trial of NanoFlu comparing various quadrivalent formulations,
with or without Novavax&rsquo; Matrix-M&trade; adjuvant, with two U.S.-licensed influenza vaccines in older adults. These results
show that NanoFlu with Matrix-M generated enhanced immune responses compared to the unadjuvanted formulation, and importantly,
showed superior hemagglutination inhibition antibody (HAI) responses against wild-type A(H3N2) viruses, including drifted strains,
when compared to Fluzone<SUP>&reg;</SUP> High-Dose, the leading flu vaccine in older adults.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Key Upcoming Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Meet with the
FDA, European regulatory agencies, and potentially other national regulatory agencies during the second and third quarters, to
assess opportunities for submission of marketing applications for ResVax.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Reach agreement
with the FDA during the third quarter of 2019 on a proposed Phase 3 clinical trial design for NanoFlu utilizing accelerated approval
criteria for licensure.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Present ResVax
Phase 3 clinical trial data at the 37<SUP>th</SUP> Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID)
on May 7, 2019.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Financial
Results for the First Quarter Ended March 31, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
reported a net loss of $43.2 million, or $0.11 per share, for the first quarter of 2019, compared to a net loss of $46.4 million,
or $0.14 per share, for the first quarter of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
revenue in the first quarter of 2019 was $4.0 million, compared to $9.7 million in the same period in 2018. This 59% decrease was
driven by the completion of enrollment of the Prepare trial in the second quarter of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Research
and development expenses decreased 20% to $35.5 million in the first quarter of 2019, compared to $44.5 million for the same period
in 2018. This decrease was primarily due to decreased development activities, including lower clinical trial costs, of ResVax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">General
and administrative expenses were flat at $8.7 million in the first quarter of 2019, compared to the same period of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Interest
income (expense), net was ($3.0) million in the first quarter of 2019, compared to ($2.9) million for the same period of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">As
of March 31, 2019, Novavax had $108.7 million in cash, cash equivalents, marketable securities and restricted cash, compared to
$103.9 million as of December 31, 2018. Net cash used in operating activities for the first quarter of 2019 was $50.6 million,
compared to $66.1 million for same period in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Conference
Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
will host its quarterly conference call today at 4:30 p.m. ET. The dial-in numbers for the conference call are </FONT>(877) 212-6076
<FONT STYLE="background-color: white">(Domestic) or </FONT>(707) 287-9331 <FONT STYLE="background-color: white">(International),
passcode </FONT>5394082<FONT STYLE="background-color: white">. A replay of the conference call will be available starting at 7:30
p.m. ET on May 2, 2019 until 7:30 p.m. ET on May 9, 2019. To access the replay by telephone, </FONT>dial (855) 859-2056 (Domestic)
or (404) 537-3406 <FONT STYLE="background-color: white">(International) and use passcode </FONT>5394082<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A
webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through
the &ldquo;Investor Info&rdquo;/&ldquo;Events&rdquo; tab on the Novavax website. A replay of the webcast will be available on the
Novavax website until August 2, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About RSV in Infants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Globally,
RSV (respiratory syncytial virus) is the leading viral cause of severe lower respiratory tract disease in infants and young children.
It is the second leading cause of death in children under one year of age. Estimated annual hospitalizations of 1.4 million and
an estimated 27,300 in-hospital deaths were due to RSV acute lower respiratory infection in children under six months of age. RSV
results in a total global economic burden of $6.2 billion annually. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In
the U.S., RSV is the leading cause of hospitalization of infants. Estimated annual hospitalizations are up to 76,000. While RSV
can impact all infants, babies under six months of age are among those at highest risk, as approximately 77% of all first-year
RSV infections occur before six months. In the U.S., the total economic burden is $2.7 billion annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ResVax&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">ResVax
is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to
protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants
through the first months of life. In February 2019, Novavax announced top-line data from Prepare&trade;, a global Phase 3 clinical
trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an
$89.1 million grant from the Bill &amp; Melinda Gates Foundation (BMGF).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Influenza</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Influenza
is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death.
Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general
population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies
in humans. An estimated one million deaths globally each year are attributed to influenza. Current estimates for seasonal influenza
vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately
$3.2 billion in 2012-13 season to $5.3 billion by the 2021-22 season. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NanoFlu&trade; and Matrix M&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">NanoFlu
is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus
system. NanoFlu uses HA protein amino acid sequences that are the same as the recommended wild-type circulating virus HA sequences.
NanoFlu contains Novavax&rsquo; patented saponin-based Matrix-M adjuvant, which is potent and well-</FONT> stimulates both high
quality and durable antibody responses as well as multifunctional CD4 and CD8 T-cell responses<FONT STYLE="background-color: white">.
In January 2019, Novavax announced positive top-line data from its Phase 2 clinical trial in older adults of quadrivalent formulations
of NanoFlu in 1,375 healthy older adults across clinical sites in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Accelerated
Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Accelerated approval
may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious or
life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments. Such an approval will be based
on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint
that is reasonably likely to predict clinical benefit. For seasonal influenza vaccines, the hemagglutination inhibition (HAI) antibody
response may be an acceptable surrogate marker of activity that is reasonably likely to predict clinical benefit. To be considered
for accelerated approval, a biologics license application for a new seasonal influenza vaccine should include results from one
or more well-controlled studies designed to meet immunogenicity endpoints and a commitment to conduct confirmatory post-marketing
studies of clinical effectiveness in preventing influenza.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Novavax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Novavax, Inc.
(Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and
commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax&trade;, its
RSV vaccine for infants via maternal immunization, and NanoFlu&trade;, its quadrivalent influenza nanoparticle vaccine. Novavax&rsquo;
proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class
of highly immunogenic nanoparticles addressing urgent global health needs<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">For
more information, visit <U>www.novavax.com</U> and connect with us on <U>Twitter</U> and <U>LinkedIn</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Statements
herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements.
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual
results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified
under the heading &ldquo;Risk Factors&rdquo; in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and
Quarterly Report on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission (SEC).
We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You
are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation
to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOVAVAX, INC.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(in thousands, except per share information)</B> <B>(unaudited)</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">Three Months Ended</P>

</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 1.5pt">Revenue</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-top: Black 1pt solid">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-top: Black 1pt solid">3,982</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; border-top: Black 1pt solid">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; border-top: Black 1pt solid">9,653</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: right; padding-left: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1.5pt">Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">35,473</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44,514</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,732</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,652</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">44,205</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,166</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Loss from operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(40,223</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(43,513</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Interest income (expense), net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(2,983</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,872</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Other income (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(12</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 1.5pt">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(43,218</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(46,352</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: right; padding-left: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 1.5pt">Basic and diluted net loss per share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1.5pt">Basic and diluted weighted average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt">number of common shares outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">408,843</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">336,972</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELECTED CONSOLIDATED BALANCE SHEET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March 31,<BR>
</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2019</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,<BR>
 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">97,711</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,154</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Marketable securities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,484</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,980</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total restricted cash</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,488</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,805</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total current assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">123,394</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,276</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Working capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">91,898</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">221,319</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">207,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Notes payable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">319,543</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">319,187</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total stockholders&rsquo; deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(150,583</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(167,935</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts: &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Investors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Erika Trahan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ir@novavax.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">240-268-2000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>john.woolford@westwicke.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">443-213-0506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !> ET# 2(  A$! Q$!_\0
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MZ\_(.F":_/G_ (*/_P#!3KQE^W_\0)XYY;C1? .GSL=)T&.3"8'2:?&/,E.
M><A,X7N3\R5^HY'P/2C%5LPUE_+T7KU9^:YQQE4<G2P.B_F[^BV/JCXR_P#!
M:3]HSXS74WG?$"Y\.6,I.+30;=+%4'IO ,A_%J^?_%OQO\:^/9_,USQ?XHU>
M0]3=ZI/-G\&8BN7S6EX6\%ZSX[U+['H>D:IK5X>D%A:27,O_ 'R@)_2ON:.!
MPN&C:G",;>2_K\3XZMC<5B'><Y2OYO\ +_@&:Q9BS9.YB223DD_6M+0/&>L>
M%IEDTW5M3TV2/[K6EW)"5/MM(KTZP_X)Y_'G4[5+B#X._$IH9!E2WAZY7/X%
M0:XWXA_L^^/?A'G_ (2OP3XM\-JO\>I:1<6L?_?4B@'\ZN.+H3?*IIOM=?YF
M7U?$0]_D:\[,]$^%O_!3#X^?!N>-M!^*GBQ8XSQ!>W7V^!OK'.'%?9W[-'_!
MRUXM\-W5O9?%;PCI_B'3\A7U+0_]%O5'')A=O*<]^"E?E_FBN#&</Y?BE:K2
M7JM']Z.["YYC\/+]W4=NSU7XG]1/[+/[:_PV_;*\'?VQX \1VNK)&!]JLV(C
MO;%C_#-"3N0^_0]B:]523S%W#]:_E+^"GQP\5?LY_$6Q\6>"]9O-"U[3VS%<
M6[<.,@E)%/RNAQRK @U_05_P2V_X*5:1_P % _A*TLRP:5XXT$+'KFE(PVY)
M(6XBSRT3X_X"WRG/!/Y;Q%PK4R]>WHMRI^>Z]?+S/TC(.)J>._=5?=J?@^]O
M\CZ"^-6@ZUXG^%VO:?X=U2;1->O-/GBTZ_C1':TN"A\M]K J0&QD$$8S7\_?
MBW_@K_\ M6>!O%FJ:'JGQ.U2TU31;N6QNX'TRR#0S1.4=3^Y[,I'X5_18Z+*
M/FYK\'O^#A?]DW_A2?[7D/CS3;4Q:%\286N)65?DCU"+ G&?5U,;^Y9_2NG@
MFIAIXB6%Q,$^973:3U737NC'B^.(AAUB</)KE>MFUH^NG5/\SR7_ (?3_M/?
M]%6U#_P6V7_QFO3_ -C#_@MC\:[?]J3P1'\0_'MQKG@N^U2*RU6VFLK6)5BF
M/E^;N2-2-C,'Z]%-?!I&*;)G'&X>XZCCJ*_3*V28&I!P]E%73U21^>4<[QM.
MI&;J2=FM+MW\M3^MZUD66W5E.Y6&01W%25\X_P#!*W]IW_AJK]AWP+XDFN/.
MU>WM?[)U56^^MU;GRF9O=U59/HXKZ.K\"Q&'G0JRHU-XMI_(_;</7C6I1K0V
MDKH****Q-C!^)OCG3_AC\/\ 6/$6JRI!IFAV<U]=2-C"11QL['GV%?SY>,O^
M"WO[2&O>+]6OM*^(EYH^F7EY+-:6*:?:,MG"SDI&"T1)VJ0,DD\5^D__  </
M?M1-\'_V-(_!>GW"KK'Q&O18LH;#+8Q#S)V^A81)])#7X1]^.G:OU#@C):,\
M-/$XB"ES.RNKZ+_@_D?G/&&<5:=>.&H2:Y5=V=M]MO(^H_\ A]/^T]_T574/
M_!;9?_&:^[/^"%7[4?Q^_;0^-?B'6O'7CW4M7\#^$;,126KV-K%'>7DP81KN
M2)6PBJSD CDIG@U^.'S,0JJ69CM4#U/2OZ0O^"1W[)__  R)^Q1X3T6ZM_)\
M0:Y$-=UK*X=+FX16\MO^N:!(_JIKLXPA@\'@N6%**E/1-16BZ_UYG+PG4Q>+
MQG-.I)Q@KO5[O1+?YGT]113)G\M1]<5^1GZ@>,?M]_M6Z=^QE^S!XI\<WC1F
M\L[8V^EP.0/ME]("L$>/3=@MCHJL>U?A:_\ P6I_:=9F9?BE?1[B6VKIEEA<
M]A^YZ#WKVC_@X5_;8/QS_:.M?AGHMUYGAWX=D_;3&P,=UJ3J-_(Z^4IV>S&0
M=J_/.OV#A/AZC#!*KBJ:E*>NJO9=-_O/ROBC/JTL7[+#3:C"ZT=KOKM]Q]1_
M\/I_VGO^BK:A_P""VR_^,T?\/J/VG_\ HJVH?^"VR_\ C-?+@YHKZ;^R<#_S
MYA_X"CYS^U\;_P _9?\ @3/Z-O\ @D+^V\_[<7[*.GZQJUQ'-XP\/N=*U\ *
MADF4 I-M&,"1"&X &X,!TKZJK^=__@BC^V@W[(O[8VGVNI70@\)^/@FB:KYC
M8CMY&<&WN3GIL?Y2>RR,>PK^AVWD\V%6!W>X[U^.\492L#C7&FO<EK'R[KY?
ME8_5^&\T>-P:E/XXZ/\ S^?YCR,U^</_  7>^.OQP_9.M/"/C;X:>-+[0O#-
M_))I6JVL5G;S)!<\O%+F2-B-Z[U/.,HO'-?H]7D7[<_[,NG_ +6W[*OC+P)>
M+&)M:LBUE*^?]'NXR)()!])%7/L2.]>;D^*IX?&0J5HJ4+V::3T>G7MN>AFE
M"I6PLX4G:5M&M'=>?GL?@_\ \/J/VG\_\E6U#_P6V/\ \9I1_P %I_VGN_Q5
MU#_P6V7_ ,9KYDUK0KWPMK-YI>I6\EKJ&FW$EI=0R+M:*5&*NI'J&!%5J_=%
ME. >JHP_\!1^,O-L:G9U)?\ @3/WS_X(6?MY^(?VR_@;X@L?'&L?VSXT\)ZD
M!/=O''#)=6DX+1-M0*ORLLB< <*.]?=M?SR?\$+_ -I?_AGK]OSP_97EQY.B
M^/8_^$=NMQPHED=3;L?I* N?20U_0TK*W0@_2OQ_B[+E@\P:IJT9:KLNZ^\_
M4^%\QEB\#%U'>4='\MG]PM%%%?,GT85^>'_!>?\ X*'^*/V/?"W@_P -_#W7
M#H?C#Q'<O?W%U'%'-);V40"8VR*P&^1QSC_EFU?H7<R&)-VY5 ZYK^;'_@K1
M^T\W[5O[=GC37;>X:XT329QHFDX.5%O;?(64CC#R>8^?]L=J^LX.RN.,QW-5
M5XP5W?:^R7Z_(^9XKS&6$P7[MVE)V7EW_KS-4?\ !:?]I[_HJNH?^"VR_P#C
M-.A_X+1_M032JB_%+4I&=@JH-,LB68\ ?ZGN:^6J^M/^"*W[)I_:J_;FT 7U
MK]H\->"_^)_JF4W(QC/^CQ'_ 'IMIP>JJU?J6.P>7X7#RQ%2C"T5?X5_6I^;
MX/&8_$UX4(597D[?$_F_D?NS^Q?HWC;0_P!F3PBGQ&UFXUWQM<6,=UJ]S-''
M&RS2 .8MJ*JXCW!.G\->IU':ILC].:DK\%JU.>;GM?L?M5.')%1WMW&R?ZMO
MI7Y6_P#!<3_@JWXR_9X^,.@_#OX4^(VT'5M*MS?>(;N*"&X;,H!@M\2*P!"!
MG;@'#I[BOT2_:C_: TG]E[X#^*?'>M2*MCX=L)+D1D@-<R[<1Q+_ +3N54>[
M"OYA?C%\5=7^.?Q5\0>,=>G:XU?Q)?2W]RQ_A9V)"CT51A0.P %?9\$Y)'%5
MWB*RO".EFKIM_P"7YV/DN+LVEA:*H4G:4GNG9I+_ (/X'OW_  ^G_:>'_-5M
M0_\ !;9?_&:=_P /J/VGL_\ )5M0_P#!;9?_ !FOENBOU'^Q\ M/8P_\!1^<
M?VMC?^?LO_ F?HW_ ,$W/^"UOQ2N/VMO#>C_ !8\:2>(/!OB9_[(E%Q:6\"V
M$\K*(;C=&BGAP%.3C;(3C(%?N#:MN@4U_)&6*\J65AR".H/;'X]Z_HR_X(_?
MMGG]LC]CC0;[4+L3>+/#&-&UU<C<TL?$<Q_ZZQ;7_P![<.U?G?'&1TZ'+B\-
M%*.TDE9>3_3[C[S@[.:E9RPN(DV]TV[W[_=N?5U?G7_P6C\0?M&_LW:>OQ,^
M%'C[5+?P7"%AUO2H[&VG.DMD*MRI:(L8F) ;).T\]"<?HIUK.\2^&;'Q3H5Y
MI^H6D-[9W\30W$$R[XYD88967H002,5\3EN,6%Q"K2BI);II--?ULSZ_,,*\
M10=*,G%OJG:S/YTA_P %I_VGL_\ )5=0_P#!;9?_ !FE_P"'T_[3W_15M0_\
M%ME_\9KI?^"OW_!,:^_81^+7]M>';6>X^&7BB9WTV;:S?V3,22;.1O8#*,?O
M+QU4Y^-SQ^/2OV[ X/+,50C7HTHN+\E]WJC\@QN+S+"UI4*U25U_>9^I'_!*
M'_@MSXTUC]H6W\'_ !L\3?VWI'BV2.UTW59[>&W.F7><(CF-5'ER9 R1\K;>
MQ-?LI;W"W"Y7VK^2/[IW+E6!R".H/J*_=7_@AA_P4O\ ^&H/A6OPY\77^[Q]
MX0ME6WFE8>9K=BO"R#UDC "OW(*MSDX^)XRX<A27U["QLEI)+;R:7YGUW"7$
M$JK^IXF5Y=&^OD_,_0NHY9UA&6.-HR3Z"E9\1;L]A7YT?\%XO^"E'_#._P -
M?^%6>$=05?&_B^U)U"X@<%]'T]LJQX^[++@JO<+N;^Z3\+EN!JXW$1P]):OK
MV75GV688RGA*$J]1Z+\?)'S7_P %/?\ @N-XZ;]HRZ\._!/Q6="\+^%]]E/?
MV]O!<?VQ<@_O'4R*X\M2-JD8SACT(KYP_P"'T_[3P_YJMJ'_ (+;+_XS7RVB
M^6N!]:55,CA%Y=CA0!DDG@<5^Y87(<#0HQI>RB[=6DV_-L_&\5GV-K595.=J
M_1-JWEH?6W@S_@KI^UG\1?%NFZ#H?Q'UG4]8UBY2TL[6#2K)Y)Y7.%4#R?\
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MOV['8JEA,/.O/X8J_P#DOGLC\<P.%J8JO&A'>3_X=_J?1O[1_P#P2!7X<?\
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M?\&O'_'C\7_^NFF?RN*^>XQ_Y%-7Y?\ I2/>X2_Y&=/Y_D?K5.,IQZU_.O\
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MG%D_-CC<Q9B.]>/YK]+X9X9_LV#J56G4EIIT7;_,_/>(^(?[0DJ=)-0B^N[
M'(J[X<\.7OC'Q!8Z3IMO)=ZAJES'9VL*#+32R,$1![EB!^-4NU?J!_P0 _X)
ML7GC7QQ9_''QCILD&AZ/(?\ A%X)TQ]ON@2INL'^"(@A2>K<C[O/M9KF5/ X
M:6(J=-EW?1'D97E]3&XB-&&S>K[+JS]5/V.O@9#^S5^S'X)\#1;6;P[I%O:S
MNHP))]N96_X%(7/XUZ938TV9IU?S[5J2J3=2>[=WZL_=*<(PBH0V6B^05^1'
M_!RM^R;Y2^%/C+IEJ=N5\/:XR+U)WO;2M^3QY]T'I7Z[UYG^V!^SUI_[5'[-
M?B_P%J"IY?B+3Y((967/V:<#=#*/=) K?A7I9'F3P.-AB.E[/S3W_P SS\YP
M*QF$G1>[6GKT/Y:ZZ+X0?$K4/@U\5_#?BW2I&BU#PWJ4&I0D'J8I%;:?8XP?
M8FL_QAX0U#X?>+-3T'5K>2TU31KJ6RNX7'S12QL49?P(-9M?OTHPJ0Y9:IK\
M#\.7-3G=:.+^YH_H%_X*B?MW:?X,_P""6MQXR\.WFV\^)^EVMEH91_FQ>1J\
MC CND!E^C "OY^$&U1]!_*O3/B=^U+XD^*WP"^'OP[U*8MHGPZ-X; ;R3)]H
MD##</]@#:OH":\UZ"O#X=R;^SJ$J;W<F[^6R_#\SVL^SCZ_5C-;**7SZ_C^1
MJ>"?!6I?$KQEI/AW1[<W6JZY>16%I".LDLKA$'XDBOZAOV3/V?=-_9?_ &<?
M"'@/353[/X<T]+>215V^?,27FD(]7E9V_P"!5^.'_!NS^R6/C+^U3??$'5+4
M2:-\.;?S+8NN5?49OEB_[XC\Q_8[*_=.-/+0+Z5\/QYF7M,1'!1>D-7ZO;[E
M^9]CP3EZIT'BY;RT7HO^#^0[I7RW_P %:OVUE_8L_9"US5K.X5?%6OYTC08\
MC=]HD'S2X](DW/\ 4*.XKZAFE\I=QZ8.3GI7\]'_  6Y_;6_X:V_;"OM-TF\
M,W@_X>M)HVG!&)CN)PY%S<#L=SJ%![K&I[UX/"^4_7L=&,O@CK+]%\V>WQ'F
MGU+!RE'XI:+U_P" ?'<LTEQ-))*[R22,6=W.YG8\DD]R3GFF]:*]D_8+_8^U
M+]N;]I;1_ &GW,FGVURKW>IWZ0B7[!:1XWR8/!.610/5Q7[C6K0HTW5J.RBK
MOT1^-X>C.M55*GK*3LCQO&:39]?SK]AXO^#7;PY)&&_X6SK@S_U!X?\ XNG?
M\0N7AO\ Z*UKG_@GA_\ BZ^<_P!=,JW]I_Y*_P#(]_\ U1S3^1?>C\=MGU_.
MC;]?SK]B?^(7+PW_ -%:US_P3P__ !='_$+EX;_Z*UKG_@GA_P#BZ/\ 73*O
M^?G_ )*_\@_U1S3^1?>C\=@ GYTIK]@[W_@UX\/P6LC0_%G6FFVG8&T>(*6[
M9^?UK\FOBA\-]5^#OQ'USPKKENUMJWAZ^ET^ZC(^Z\;%21['&1Z@BO2RW/<'
MCVXX:?,UJ]&OS/.S#)<5@8J>(C9/SN8/Z>XZCZ5_0W_P1/\ VU&_:Z_8^TVW
MU2\6X\6>!@FB:MN8>9.J(/(N#Z[XP 3W='K^>2OJK_@CQ^V@W[&O[8^BW6H7
M+1>$O%A&BZXI8JB(YQ#,>V8Y2IS_ '6?UKS^+,I^NX)N*]^&J_5?,[^&,S^J
M8U*7PRT?Z/Y']&U8/Q.\ Z7\5/A[K/AG6K<76DZ]9RV%Y$1D/%(A1A^1K:M)
MA<0AUP5;D$'.1ZTYTWBOP^[B[K=?F?L<HJ2Y9;?H?RM?M,? O4OV9?C[XL\!
MZNK?;?#.H26F]EV^=%]Z&0>SQ,C?\"KAJ_5C_@Y;_9+.E^*/"OQDTNWQ!J 7
M0=<95_Y:JI:VD;ZJ'3)_N**_*>OZ R7,ECL'#$+>VOJM'_79GX;G.!>"QDZ'
M2]UZ,_4K_@V?_:5.@_$?QI\*KRX*P:Y -=TM6/ GB&R=5'JT9C;Z1&O$O^"^
MG[3I^/G[<M[H-G<^=HOPYM1HD:*V4-T6,ERX_P!K<5C_ .V5?+W[,'[0.L?L
MK_'SPU\0-!^;4O#MR9EB+%%N$9&C>-B.S([ _6N1\3>([WQCXDU#5]2G:ZU'
M5;F2\NIF.6EED8N['ZL2:XZ.1QAFTLPZ.*^3V?X+\3LJ9S*651P"W4G?_"M5
M^+_ HU^C?_!N5^R7_P +1_:0U?XG:I;>9H_@&$6]@77*OJ$ZX!'O'$&/L9$-
M?G($:5E2,,TDAVHJC+,QZ >YK^E3_@EI^R6O['_[%OA#PS/;I#KEU#_:NLMC
MYFNYSO92>_EJ5C'M&*X^,\S^JX%TX/WIZ+TZO[M/F=/"&7_6<:JLE[L-?GT_
MS^1]%*@3I1,VR,FG5YK^UO\ M'Z/^RG^SMXJ\>:TR_9/#]F94CSS<SL0D,0]
MWD95XZ9SVK\8ITY3FJ<-V[+U9^MU*BA!SGLE=GY7_P#!R#^VPWBWQ]H_P6T.
M[W:?X?V:KKYC;A[ME;R8&_W(SO(]9%_NU^7-;GQ,^(VK_&#XAZUXJUZY>\UK
MQ%>RZC>2L<[I)&+''L,X [  5AY_SZ5_0.49=# X2&'6ZW?=O=_?^!^&9MF$
ML;BI5WL]O1;+]0)HQ]?SK[Z_X)G?\$1Y/V[/@//X[U[Q5J'A'3[R_>VTE(+%
M)S>1Q_))*2S# $@9!USL:OH[_B%R\-_]%:US_P $\/\ \77#B.*\MH594:E3
MWH[JS?Z'=AN&<QK4HUJ4%RRVUL?CMMSZ_G1L^OYU^Q/_ !"Y>&_^BM:Y_P""
M>'_XNC_B%R\-_P#16M<_\$\/_P 76/\ KIE7_/Q_^ O_ "-_]4<T_D7WH_'?
M;06YZU^Q'_$+EX;_ .BM:Y_X)X?_ (NOE#_@JA_P2!N/^"=W@OPWXDTGQ+?>
M+-!U:[>PO9I[18#8SE=\7"L00X#C/&"H]:Z,'Q1EV)JJA1J>\]E9K]#GQ/#>
M/P]*5:M'W5O9IGQ-7VY_P0>_;.;]F+]L&W\,ZI<M#X5^)&W2[DLV$M[P;C;2
MX]V/E$^D@/\ #7Q'TJ2UNYK"YCGMY)(9X7#QR(VUHV'((/8@\UZN88&GB\//
M#5-I*WIV?R9YN QD\+B(UZ>\7]_=?-']7GCWXD:/\+_!>I^(M>U*WTO1='MV
MNKR[N&"I!&HR2?\ //2OYV?^"H/_  43UC_@H'\;VOD:XL? ^@NT.@:8YQA>
M]S(O_/5^O/W1A1W)Z/\ ;O\ ^"NOB_\ ;3^!?@GP*WVC2=-TO3X6\2LDF&UZ
M_3*[VQ_RR&%<(?XR2>BU\A5\EPIPJ\$_K&*_B;+R7?U?Y'U/$W$BQ2^KX9OD
MW?F]-/1 !@5[1^P5^Q=KO[=7[1&E>#=)62WTY6%UK6HA-RZ;9J?G?TWM]U!G
MEB.P)'DWA/PMJ7COQ3IVAZ-9W&HZMJUS'9V=K"-TD\LC!451[D@5_1?_ ,$K
M?^"?FF_L&?L[6^ERQPW'C+70E[XBO@HS)/@E8%/7RXMQ51W)9OXJ]+B?/%E^
M&]S^)*Z7^?R_,\SAO)7C\1>?P1:;\_+Y_D?GK_P6K_X)$Z;^SYX/TOXE_"W1
MY+;PKI=K!IVOZ?'E_LFP+''>CN0_"R'^]AN[&OS+[5_6;XN\+Z?XR\)ZAH^K
M6EOJ&FZE;M;75M.@>.>-AAD8'@@@D5_.E_P56_X)ZZA^P-^T%-:V<<]QX%\2
M,]WX?O6^8(N3NM7;_GI'Q_O*5/KCQ^#^(I8B/U/$N\ULWNUU7JOQ1Z_%V1*C
M+ZYAU:+W2Z/_ "?YGR^1N'-?LY_P0=_X*H-\4-$L_@KX^U+_ (J+28=OAS4+
MF3+:K;K_ ,NSL>LL8^[SED&.J\_C'5SPYXEU#P9XAL=8TJ]N=.U/2YTNK2ZM
MW*2V\J,&5U(Y!! .1Z5]/G63TLQPSH3T?V7V?];GS>3YK5P%=5H;?:7=?Y]C
M^M0-FBOCW_@D5_P4LL?V\?@M]EU:6WM_B)X9CCAUFT4[?M2\A;J,?W7P=P'W
M6R.A7/V$IR*_",9@ZN%K2H5E:43]KPF*IXBDJU)W3"BBBN4Z#^1_-"N P^M?
MT9?\.0?V7O\ HEEC_P"#2^_^/4U_^"(/[+[?+_PJRQY_ZBE]_P#'J_7O]?L!
M_)/[E_F?EW^HN+Z5(_B._P""(I_XUC_"\=Q:7.?_  +GKZNKE/@I\%/#7[//
MPXT[PCX0TU=)\/:2K):6BR/(L(9V<@,Y+'YF)Y)ZUU=?E>.KJMB:E:.TI-_>
M[GZ1@Z+I8>G2>\8I?<D@KX;_ ."XG[ ?_#6O[-#>)=!L_,\<^ E>]LQ&N9+^
MTP3/;>I) #J.NY,?Q&ON2F31B9"K?=_G1@<94PE>.(I;QU_S7S0L;A88FC*C
M4V:_I_(_DB/![CU![49K^CWQ!_P1?_9H\5:]?:I??"_3I+S4;B2ZG=+^[B5I
M'8LQ"K*%7DG@ "JG_#D']E[_ *)98_\ @TOO_CU?JD>/\!;6$_N7^9^<RX%Q
M5]*D;?/_ "/YS<U^N7_!KPW^A?%__KIIG\KBOL#_ (<A?LOC_FEEC_X,[[_X
M]7JO[-'[$/PO_8_CU5/AQX7A\-+KAC:^$5S--YYC#;,^:[8QN/3'6O'X@XPP
MF-P,\+2C)2E;>UM&GT;['J9+PKB,%C(XB<TTNU^NAZS3)(P^[Y1]:?17YR?>
M'Q'_ ,%,?^",OA/]N43^)]!EM_"/Q'2+:-0"?Z+JN  JW2 9R ,"1?F&>0P
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M?"0H8F,G*.EU9Z=-VNFA^?YMP?5Q&+E5H245+6SOOUV/YSLXI"P_7%?T9_\
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MX$^V"BBB@!K('&"-WUK\5_\ @Y$_8^'@/XQZ+\7M'M@NG^,%73=:*+A8[V%
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MX9_;9^!6D^-O#4VU;I!#J%D[ S:;=!1YD#C/4$\'HP((ZU_+[7TE_P $Q_\
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8RDMK^?KW/T#A'/7;ZEB&VEL^OI_D?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
